Acuta Capital Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Acuta Capital Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-17,500	Closed	-$1.76M	–	57
2021 Q3	$1.76M	Buy	17,500 +7,500	+75%	+$879K	0.62%	35
2021 Q2	$1.42M	Sell	10,000 -4,000	-29%	-$452K	0.57%	35
2021 Q1	$1.4M	Buy	+14,000	New	+$1.63M	0.5%	41
2020 Q3	–	Sell	-15,300	Closed	-$2.39M	–	57
2020 Q2	$2.39M	Sell	15,300 -8,200	-35%	-$1.25M	0.69%	39
2020 Q1	$3.39M	Sell	23,500 -14,500	-38%	-$2.8M	1.64%	21
2019 Q4	$7.77M	Sell	38,000 -7,000	-16%	-$1.28M	1.92%	18
2019 Q3	$3.61M	Buy	+45,000	New	+$3.82M	2.61%	14

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Acuta Capital Partners's RETA Position: Q4 2021 in Review

Acuta Capital Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 17,500 shares — an estimated $1.76M sold.

Acuta Capital Partners first reported a position in RETA in Q3 2019 and held it in 7 quarters. The position peaked at $7.77M in Q4 2019. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

Acuta Capital Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Acuta Capital Partners sold 17,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $1.76M.
Acuta Capital Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 7 quarters.
Acuta Capital Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $7.77M in Q4 2019.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Acuta Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.